Future FinTech Signs Framework Agreement to Acquire TransGen SC Tech Limited Expanding into the Biomedical R&D Sector
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Future FinTech (NASDAQ:FTFT) said its subsidiary Future FinTech (Hong Kong) Limited signed a Framework Agreement on Jan 7, 2026 to acquire 100% of TransGen SC Tech Limited, a biomedical R&D company focused on diabetes, Alzheimer’s and microalgal extracellular vesicle drug-delivery research.
The acquisition is expected to complete within 90 calendar days subject to due diligence and a financial audit; a definitive agreement will follow a satisfactory outcome. TransGen holds 26 invention and utility patents and certifications including Level 2 Biosafety Laboratory and Human Umbilical Cord Mesenchymal Stem Cells qualification.
Positive
- Framework agreement to acquire 100% of TransGen signed on Jan 7, 2026
- TransGen holds 26 invention and utility patents
- TransGen has Level 2 Biosafety Laboratory certification and stem cell qualification
- Deal aims to diversify FTFT into biomedical R&D and leverage fintech capabilities for funding
Negative
- Completion is conditional: subject to due diligence and financial audit
- No financial terms or purchase price were disclosed
- Targeted closing timeline of 90 calendar days is an expectation, not guaranteed
Details
News Market Reaction – FTFT
On Jan 8, the day this news came out, FTFT closed 9.25% below the previous close.
Data tracked by StockTitan Argus for the Jan 8 session.
Key Figures
- Acquisition stake
- 100% of TransGen shares
- Framework Agreement signed Jan 7, 2026
- Closing timeline
- 90 calendar days
- Expected completion of TransGen acquisition, subject to due diligence and audit
- Patent portfolio
- 26 patents
- TransGen invention and utility model patents
- Q3 2025 revenue
- $1,324,633
- Quarter ended September 30, 2025
- Q3 2025 loss from continuing ops
- $1,965,312
- Quarter ended September 30, 2025
- Nine‑month loss from continuing ops
- $31,058,936
- Nine months ended September 30, 2025
- Gain on disposal
- $28,238,122
- Gain on disposal of discontinued operations, nine months 2025
- Cash balance
- $6,891,224
- As of September 30, 2025
Historical Context
-
LOI with S1Quant to build compliant quantitative crypto asset management products.
-
Strategic cooperation with HHEX to accelerate Web3 and RWA tokenization platforms.
-
JV to commercialize patented ultra‑high‑speed rail ‘Vacuum Parcel’ transport technology.
-
Announcement of special shareholder meeting and voting logistics for investors.
-
Launch of AI-driven analytics and trading platform via Hong Kong securities subsidiary.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
microalgal extracellular vesicles medical
nanocarriers medical
mesenchymal stem cells medical
biosafety laboratory medical
extracellular vesicles medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Pursuant to the Agreement, the acquisition is expected to be completed within 90 calendar days subject to due diligence and a financial audit of TransGen. A formal acquisition agreement will be executed upon a satisfactory outcome, after which both parties will sign a definitive agreement.
TransGen has established a solid foundation in biofactor R&D, which entails processes that leverage naturally occurring compounds that support normal physiological functioning and that have health-promoting effects on disease prevention and overall wellness. TransGen's primary focus is on the high-value therapeutic areas of developing treatments for diabetes and Alzheimer's disease.
TransGen also conducts advanced research on the enrichment and functional properties of microalgal extracellular vesicles – naturally secreted nanoparticles from microalgae. These serve as next-generation nanocarriers for targeted drug delivery and diagnostics by harnessing their natural ability to transfer beneficial biological molecules. TransGen holds 26 invention patents and utility model patents. This includes numerous certifications and designations, including:
Level 2 Biosafety Laboratory Certification, which refers to standards and protocols for laboratories involved in moderate risk infectious agents, which is regulated by
Human Umbilical Cord Mesenchymal Stem Cells Qualification Certificate, that ensures the quality and safety of pharmaceuticals and biological products, issued by
TransGen has also played an instrumental role in the formulation of the group standard "Specification for Isolation and Preparation of Adipose-Derived Mesenchymal Stem Cells" and the local standard "Standards and Management Specifications for Human Mesenchymal Stem Cell Banks", underscoring its strong technological capabilities and recognized leadership within the industry.
Gai Wei, Director of TransGen, said, "TransGen focuses on technology R&D and industrialization in the biomedical field, possesses core technologies and compliance qualifications in areas such as biofactor therapy and microalgal extracellular vesicle research, and is committed to improving human health and well-being through biological innovation technologies. The signing of this agreement with Future Fintech marks a pivotal step for TransGen to partner with a globally resourced company to advance its international expansion strategy."
Hu Li, CEO of FTFT, stated, "The signing of this agreement represents our strategic plan to diversify into the biomedical sector since TransGen is poised for high growth and is well positioned in a large market driven by an aging population and rising healthcare spending. Further, our fintech capabilities in risk modeling, securitization and capital markets can be used to structure innovative funding vehicles for medical-device initiatives, turning biomedical R&D into investable products. We also see synergies for FTFT since secure identity, payments, and data sharing are critical in both finance and healthcare. This acquisition will help to promote the industrialization of TransGen technologies while delivering diversified long-term value for our shareholders."
About Future Fintech Group Inc.
Future FinTech Group Inc. (NASDAQ: FTFT) is a comprehensive financial and digital technology service provider. The Company, through its subsidiaries, conducts brokerage and investment banking services in
Safe Harbor Statement
Certain statements made in this press release are "forward-looking statements" within the meaning and protections of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements include statements regarding our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties, and other factors that may be beyond our control, which may cause the actual results, performance, capital, ownership, or achievements of the Company to be materially different from those implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements by our use of words such as "may," "will," "anticipate," "assume," "should," "indicate," "would," "believe," "contemplate," "expect," "estimate," "continue," "plan," "point to," "project," "could," "intend," "target" and other similar words and expressions relating to the future.
All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary notice, including, without limitation, the risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2024 and our other reports and filings with the SEC. Such reports are available upon request from the Company, or from the Securities and Exchange Commission, including through the SEC's Internet website at http://www.sec.gov. We have no obligation and do not undertake to update, revise, or correct any of the forward-looking statements after the date hereof, or after the respective dates on which any such statements are otherwise made.
View original content to download multimedia:https://www.prnewswire.com/news-releases/future-fintech-signs-framework-agreement-to-acquire-transgen-sc-tech-limited-expanding-into-the-biomedical-rd-sector-302655687.html
SOURCE Future FinTech Group Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.